IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Mo, Xiao-Dong1,2; Zhang, Xiao-Hui1,2; Xu, Lan-Ping1,2; Wang, Yu1,2; Yan, Chen-Hua1,2; Chen, Huan1,2; Chen, Yu-Hong1,2; Han, Wei1,2; Wang, Feng-Rong1,2; Wang, Jing-Zhi1,2; Liu, Kai-Yan1,2; Huang, Xiao-Jun1,2,3,4
关键词Donor Lymphocyte Infusion Hematopoietic Stem Cell Transplantation Ifn-alpha Minimal Residual Disease Preemptive
刊名BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2015-11-01
DOI10.1016/j.bbmt.2015.06.014
21期:11页:1939-1947
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Immunology ; Transplantation
研究领域[WOS]Hematology ; Immunology ; Transplantation
关键词[WOS]VERSUS-HOST-DISEASE ; ACUTE MYELOID-LEUKEMIA ; DONOR LYMPHOCYTE INFUSION ; BONE-MARROW-TRANSPLANTATION ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; IN-VITRO ; MYELODYSPLASTIC SYNDROME ; COMORBIDITY INDEX ; WORKING PARTY ; FREE SURVIVAL
英文摘要

In this prospective clinical study, the safety and efficacy of preemptive interferon-alpha (IFN-alpha) treatment were investigated and compared with preemptive donor lymphocyte infusion (DLI) in patients who were minimal residual disease (MRD)-positive after allogeneic hematopoietic stem cell transplantation (HSCT). Patients undergoing allogeneic HSCT were eligible if they had acute leukemia or myelodysplastic syndrome and were MRD-positive after HSCT. Patients who were able to receive DLI were assigned to a preemptive DLI group (n = 45); patients who could not or did not agree to receive DLI after HSCT received preemptive IFN-alpha. A total of 22 patients received preemptive IFN-alpha; the median treatment duration was 35 days (range, 4 to 180 days). Seven patients relapsed, and 1 patient died from severe pneumonia. The 1-year cumulative incidence of chronic graft-versus-host disease (cGVHD) after intervention was 90.9% for the IFN-alpha group and 62.9% for the DLI group (P < .001). MRD status after preemptive intervention was comparable in the 2 groups, and the 1-year cumulative incidence of relapse after intervention was 27.3% for the IFN-alpha group and 35.6% for the DLI group (P = .514). The 1-year cumulative incidence of nonrelapse mortality after intervention was 4.5% for the IFN-alpha, group and 4.4% for the DLI group (P = .985). The 1-year probability of disease-free survival after intervention was 68.2% for the IFN-alpha group and 60.0% for the DLI group (P = .517). In multivariate analysis, early-onset MRD, persistent MRD after intervention, and absence of cGVHD after intervention were significantly associated with poorer clinical outcomes. Thus, preemptive IFN-alpha may be a potential alternative for MRD-positive patients who cannot receive preemptive DLI after HSCT. (C) 2015 American Society for Blood and Marrow Transplantation.

语种英语
WOS记录号WOS:000363357200013
项目编号81230013 ; 2013AA020401 ; 30971292 ; 81400145
资助机构Key Program of the National Natural Science Foundation of China ; National High Technology Research and Development Program of China (Program 863) ; National Natural Science Foundation of China
引用统计
被引频次:15[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51952
专题北京大学第二临床医学院
医学人文研究院/公共教学部_哲学与社会科学系
北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing 100044, Peoples R China
3.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
4.Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Mo, Xiao-Dong,Zhang, Xiao-Hui,Xu, Lan-Ping,et al. Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2015,21(11):1939-1947.
APA Mo, Xiao-Dong.,Zhang, Xiao-Hui.,Xu, Lan-Ping.,Wang, Yu.,Yan, Chen-Hua.,...&Huang, Xiao-Jun.(2015).Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,21(11),1939-1947.
MLA Mo, Xiao-Dong,et al."Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation".BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 21.11(2015):1939-1947.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mo, Xiao-Dong]的文章
[Zhang, Xiao-Hui]的文章
[Xu, Lan-Ping]的文章
百度学术
百度学术中相似的文章
[Mo, Xiao-Dong]的文章
[Zhang, Xiao-Hui]的文章
[Xu, Lan-Ping]的文章
必应学术
必应学术中相似的文章
[Mo, Xiao-Dong]的文章
[Zhang, Xiao-Hui]的文章
[Xu, Lan-Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。